IntroductionNearly two decades ago, Gibco™ CTS™ Dynabeads™ CD3/CD28technology was used in the first pioneering, clinically approvedCAR T cell therapy [1]. The antibody-coated magnetic beadswere crucial in the manufacturing process to achieve one-stepcell isolation and activation, and enabled clinical-scale doseproduction within 2 to 3 weeks. Since then, the technology hasbecome well established in the industry and has been used inover 200 clinical trials to provide critically needed treatment forpatients
提供商 |
賽默飛世爾科技（中國）有限公司 | 下載次數(shù) |
0次 |
資料大小 |
384.6KB | 資料類型 |
PDF 文件 |
資料圖片 |
-- | 瀏覽次數(shù) |
108次 |
(空格分隔,最多3個,單個標(biāo)簽最多10個字符)
3
立即詢價
您提交后，專屬客服將第一時間為您服務(wù)